[Thrombocytopenia in patients with chronic hepatitis C].
This article represented a modern view on the problem of thrombocytopenia in patients with chronic hepatitis C, including it's role as an adverse event of antiviral therapy. According to the literature the prevalence was analyzed and the main aspects of pathogenesis, possible ways of treatment of thrombocytopenia were discussed.
Bakulin
I G
IG
Sharabanov
A S
AS
Moliarenko
E V
EV
Iakovleva
E V
EV
D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D018450:Disease Progression; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000453:epidemiology
D000998:Antiviral Agents; D015415:Biomarkers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a